Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.

Weinhold, Niels; Ashby, Cody; Rasche, Leo; Chavan, Shweta S; Stein, Caleb; Stephens, Owen W; Tytarenko, Ruslana; Bauer, Michael A; Meissner, Tobias; Deshpande, Shayu; Patel, Purvi H; Buzder, Timea; Molnar, Gabor; Peterson, Erich A; van Rhee, Frits; Zangari, Maurizio; Thanendrarajan, Sharmilan; Schinke, Carolina; Tian, Erming; Epstein, Joshua; Barlogie, Bart; Davies, Faith E; Heuck, Christoph J; Walker, Brian A; Morgan, Gareth J.
Blood; 128(13): 1735-44, 2016 09 29.
Artigo em Inglês | MEDLINE | ID: mdl-27516441
To elucidate the mechanisms underlying relapse from chemotherapy in multiple myeloma, we performed a longitudinal study of 33 patients entered into Total Therapy protocols investigating them using gene expression profiling, high-resolution copy number arrays, and whole-exome sequencing. The study illustrates the mechanistic importance of acquired mutations in known myeloma driver genes and the critical nature of biallelic inactivation events affecting tumor suppressor genes, especially TP53, the end result being resistance to apoptosis and increased proliferation rates, which drive relapse by Darwinian-type clonal evolution. The number of copy number aberration changes and biallelic inactivation of tumor suppressor genes was increased in GEP70 high risk, consistent with genomic instability being a key feature of high risk. In conclusion, the study highlights the impact of acquired genetic events, which enhance the evolutionary fitness level of myeloma-propagating cells to survive multiagent chemotherapy and to result in relapse.
Selo DaSilva